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Background: The small delta antigen protein of hepatitis delta virus (HDV) has been 
shown to be important for replication of the virus and essential for the viral life cycle. 
Therefore, it may be an appropriate target for designing biological experiments for drug 
development to identify the potential inhibitors of hepatitis D.
Objectives: To identify a novel molecule as possible drug candidate for the treatment of 
Hepatitis D. 
Materials and Methods: In the present study, a computational approach was used for the 
identiﬁcation of novel small-molecule inhibitors against HDV replication using docking 
studies. An Autodock tool was used for docking and identifying the active binding sites 
in target proteins. The Lipinski ﬁlter and preADMET program were also used for deter-
mining the pharmacokinetic properties in order to ﬁlter out potential ligand molecules 
to restrain virus replication. 
Results: Our results suggest that pyridinone (3-[(4,7-dichloro-1,3-benzoxazol-2-yl) 
methylamino]-5-ethyl-6-methyl-pyridin-2(1H)-one) is a validated potential inhibitor of 
HDV replication and could be as a novel antiviral drug for the treatment of hepatitis D. 
Counclusions: We have identiﬁed a novel antiviral drug by using innovative computa-
tional approaches. The results provide a basis to experimentally develop into drug which 
can be used for the treatment of delta hepatitis. 
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1. Background
Delta hepatitis currently aﬀects about 20 million peo-
ple worldwide (1). It is more prevalent among popula-
tions using injectable drugs, particularly, in countries 
bordering the Mediterranean Sea, while it is least com-
mon in Eastern Asia, although it is present in Taiwan, 
China, and India. Most child cases of delta hepatitis have 
been identiﬁed in Italy and Greece, and a few have been 
identiﬁed in northern Africa. The disease is caused by 
hepatitis delta virus (HDV), which was discovered in 1977 
by Rizzetto and colleagues while they were studying liver 
biopsy samples of patients with hepatitis B surface anti-
gen (HBsAg)-positive chronic liver disease (2). HDV is an 
RNA virus and subviral satellite of hepatitis B virus, on 
which it is dependent for its envelope proteins (3). The 
HDV genome, the smallest among animal pathogens, is 804
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a single-stranded negative sense circular RNA of about 
1,700 nucleotides in length that forms a highly base-
paired rod-like structure (4). The HDV genome has a 
single open reading frame that encodes a single protein, 
the delta antigen protein (dAg). There are 2 forms of the 
delta antigen. The small form (195 amino acid long) is 
essential for HDV replication, and the large form, which 
has a 19-amino-acid extension at the carboxyl end (214 
amino acid long), is crucial for virion packaging.
Assembly of HDV in infected human hepatocytes in-
volves the association of the single-stranded genomic 
RNA with multiple copies of both small and large forms 
of the delta antigen protein to form a ribonucleoprotein 
particle, which in turn interacts with envelope proteins 
of the natural helper virus, hepatitis B virus, for the ini-
tiation of a new round of replication (5). During HDV 
replication, 3 HDV RNA species are produced: the 1.7-kb 
antigenome, 1.7-kb genome, and 0.8-kb antigenomic-
sense RNA. The former 2 RNA species form circular RNA 
and represent the replication products of the HDV RNA 
genome. The 0.8-kb RNA, however, is polyadenylated 
and thus resembles cellular pol II transcripts. This RNA 
acts as the mRNA for the translation of HDAg (6). In HDV-
infected cells, both small (S-HDAg) and large (L-HDAg) 
forms of HDAg are found (7-10). Both forms are trans-
lated from the same open reading frame present on the 
0.8-kb mRNA; the large form results from an RNA editing 
event (11-13), extending the S-HDAg open reading frame 
by 19 amino acids to encode the L-HDAg. The S-HDAg is 
required for HDV RNA replication in vivo (14). In contrast, 
the L-HDAg inhibits the replication of HDV RNA (15, 16). 
The three-dimensional structure of S-HDAg protein of 
HDV was previously designed using threading by using a 
homology modeling approach. The model was evaluated 
according to the geometric design, fold recognition pat-
tern, and compliance to the criteria for a quality model 
(17), which was used as a receptor in the present study.
Identiﬁcation of new drug-like candidates is a crucial 
step in the early phase of drug discovery. The primary 
goal is to select a small number of compounds with de-
sired properties (i.e. bioactivity against a drug target) 
from hypothetically available screening compounds 
(18). The number of synthetically accessible organic mol-
ecules has been estimated to be in the range of 1,060 to 
10,100 (19, 20). Hence, the comprehensive screening of 
such large number of compounds is evidently impos-
sible. Advancement in high-throughput screening (HTS) 
and parallel synthesis since the early 1990s have acceler-
ated the pace for developing of active molecules (21), and 
large compound libraries can be developed in a combi-
natorial fashion and screened with the help of robotics 
(22). HTS is considerably costly and does not always yield 
many validated hits (23-25). On the other hand, computa-
tional approaches like similarity searches (26), pharma-
cophore searching (27), molecular docking (28), quan-
titative structure-activity relationship (QSAR) methods 
(29), and de novo design (30) are useful to select tens to 
hundreds of compounds with predicted desired activity. 
Computational methods are successfully being applied 
in the selection and prioritization of putative drug tar-
get genes, computational modeling and X-ray structure 
validation of protein targets with drug lead compounds, 
simulated docking and virtual screening of potential 
lead compounds, and lead validation, etc., to develop 
new antiviral drugs. By facilitating the identiﬁcation of 
active sites, characterization of conserved residues and, 
where relevant, prediction of catalytic residues, bioin-
formatics provides information that helps in designing 
selective and eﬃcacious drug-like molecules (31). 
2. Objectives
The aim of present study was to identify a novel anti-
viral molecule against HDV using virtual screening and 
docking strategies. An eﬀective drug against hepatitis 
D has not yet been identiﬁed. Hence, there is a need to 
identify a suitable candidate for targeting HDV. We hope 
that our study results enable the identiﬁcation of a new 
drug molecule.
3. Materials and Methods
3.1. Retrieval of the Three-Dimensional Structure of S-
HDAg
The three-dimensional structure model of small delta 
antigen (S-HDAg) protein of HDV was retrieved from 
Protein Model Database (http://mi.caspur.it/PMDB/) as 
PM0075974 and used as a receptor for docking in the 
present study.
3.2. Ligand Selection
Several replication inhibitors were chosen from the Na-
tional Centre for Biotechnology Information (NCBI) Pub-
Chem compound database as ligand molecules having 
the ability to inhibit the replication of S-HDAg protein of 
HDV. These molecules were downloaded in Structure-Da-
ta File (SDF) format and converted to Protein Data Bank 
(PDB) coordinates by using Open Babel (http://openba-
bel.org) converter. The selected ligand molecules were 
passed through the Lipinski ﬁlter (http://www.scfbio-
iitd.res.in/utility/LipinskiFilters.jsp) for identifying their 
drug-like properties and only the molecules that passed 
through this ﬁlter were used for further analysis.
3.3. Receptor and Ligand Optimization
PDB coordinates of the small delta antigen protein and 
ligand molecules were optimized using Gromacs 4.0 
suite (32) force ﬁeld analysis and UCSF Chimera (http://
www.cgl.ucsf.edu/chimera) tools, respectively. The opti-
mized structures had minimum energy conﬁrmation, 
which provided stability to the structure. These opti-
mized receptor and ligand molecules were used for the 
docking study. 805
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3.4. Docking Setup 
Automated docking was used to determine appropriate 
binding orientations and conformations of various in-
hibitors at the target site. Autodock 4.0 (33) was used for 
docking of inhibitor molecules with S-HDAg protein of 
HDV, and Lamarckian Genetic Algorithm (LGA) was used 
to determine the globally optimized conﬁrmation. Polar 
hydrogen atoms were added, and Kollman charge, atom-
ic solvation parameters, and fragmental volumes were 
assigned to the protein using Autodock tools. The grid 
spacing was 0.375 Å for each spacing; each grid map con-
sisted of 60 × 60 × 60 grid points, and 57.748, 57.623, and 
57.694 coordinates. During each docking experiment, 25 
runs were performed, and the population size was set at 
150; maximum number of evaluation, 2,500,000; maxi-
mum number of generations, 27,000; rate of gene muta-
tion, 0.02; and cross-over rate, 0.8. The remaining param-
eters were set as default. A root mean square deviation 
(RMSD) tolerance for each docking was set at 2.0 Å. Every 
inhibitor molecule had 0.274 coeﬃcients of torsional 
degrees of freedom for docking. At the end of docking, 
a cluster analysis was performed. For docking of each 
ligand, all the conﬁrmations were clustered together 
and ranked by the lowest binding energy. These docked 
complexes were subjected to further analysis. Autodock 
Vienna (34) and Patchdock tools (35) were used to check 
the accuracy of the results.
3.5. ADME/T Properties Calculation
Absorption, Distribution, Metabolism, Excretion, & Tox-
icity (ADME/T) properties of the selected inhibitor mol-
ecules were calculated using the preADMET online server 
(http://preadmet.bmdrc.org/) and PK/DB tool (36). This 
program calculates the human intestinal absorption, in 
vitro Caco-2 cell permeability, Maden Darby Canine Kid-
ney (MDCK) cell permeability, skin permeability, plasma 
protein binding, blood brain barrier penetration, and 
carcinogenicity.
4. Results 
Innovative computer-assisted approaches have been 
applied to identify new antiviral agents. The S-HDAg 
functions as a trans-activator of HDV replication cycle. 
The three-dimensional structure of S-HDAg protein of 
HDV was used in this study as a receptor. The length of 
the S-HDAg protein sequence is 195 amino acid; expected 
weight, 21,936.6 Da; and isoelectric point (pI), 10.02. 
4.1. Screening and Optimization of Inhibitors 
The S-HDAg protein of HDV has been reported to play 
a major role in the replication process. Therefore, repli-
cation inhibitors were required to block the replication 
process. We selected 38 replication inhibitors from the 
PubChem compound database as ligand molecules. De-
tails of the selected molecules and their physiochemi-
cal properties, drug-like properties, and 2D structures 
are given in supplementary Table 1. Some inhibitors that 
did not follow the 5 Lipinski rules, –i.e., not more than 
5 hydrogen bond donors, not more than 10 hydrogen 
bond acceptors, molecular weight not greater than 500 
daltons, and an octanol-water partition coeﬃcient log 
P of not more than 5 (37), or those that had a polar sur-
face area of less than 140 Ǻ, as suggested by Arup et al. 
(38), were discarded at various steps as shown in the ﬂow 
chart in Figure 1. After this ﬁltration step, only 29 molecu-
lar inhibitors remained that were used for further analy-
sis.
The PDB coordinates of the S-HDAg protein (as receptor) 
and inhibitor (as ligand) molecules were optimized us-
ing Gromacs and Chimera tools to attain their minimum 
energy conﬁrmation and obtain a thermodynamically 
stable structure. Next, the receptor and ligands were sub-
jected to docking using Autodock 4.1.
4.2. Docking and Active Site Studies
Autodock 4.1 was used to dock inhibitors to identify the 
active entities and determine the active binding sites in 
target proteins. Lamarckian Genetic Algorithm (LGA) for 
docking was implemented with deﬁned parameters for 
determining the docking performance. The output of 
molecular docking was clustered to determine the bind-
ing free energy (BE) and optimal docking energy confor-
mation that is considered as the best docked structure, 
as well as to elucidate their binding state in the receptor. 
BE for each docking was calculated using a semi-empiri-
cal free energy force ﬁeld with charge-based desolvation 
and grid-based docking. The force ﬁeld was decided on 
the basis of a comprehensive thermodynamic model 
that allows the incorporation of intermolecular energies 
into the predicted BE (33). It also included a charge-based 
method for the evaluation of desolvation. The method 
was designed to use a typical set of atom types. The for-
mula for calculating semiempirical BE is given below:
ΔGbinding = ΔGvdw + ΔGelec + ΔGhbond+ ΔGdesolv + ΔGtors + ΔGintermol, 
where ΔGvdw = Vander wall or Lennard–Jones potential, 
ΔGelec = electrostatic factor with distance-dependent di-
electric, ΔGhbond = H-bonding potential with directional-
ity, ΔGdesolv = charge-dependent variant of volume-based 
atomic solvation, ΔGtors = torsional energy based on the 
number of rotatable bonds, and ΔGintermol = intermolecular 
energy of protein and ligand molecules (33). The sum-
mations were performed over all pairs of ligand and pro-
tein atoms, and the BE was calculated. Docking was also 
performed to determine the inhibition constant (Ki) for 
drug-like molecules and to calculate the RMSD value.
Most docked inhibitors interacted in the same fash-
ion and showed more hydrogen bonding with GLU156, 
GLY157, GLY158, GLY161, and ASP46 amino acids (Figures 
2, 3, and 4). The binding modes and geometrical orienta-
tion of all compounds were almost identical, suggesting 
that all the inhibitors occupied a common cavity in the 
receptor. The binding pattern of each inhibitor molecule 
with an active site and the hydrogen bond distance in 
the target protein are shown in supplementary Table 2. 806
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Autodock BEs (ΔGbind, kcal/mol), calculated using diﬀer-
ent energy solution and inhibition constants for each 
protein-ligand complex are shown in Table 1. Among the 
molecules tested, pyridinone (CID_65002) showed the 
lowest BE, i.e., -7.55 kcal/mol. In other words, it had the 
highest potential binding aﬃnity for the binding site of 
the target protein.
For conﬁrming the accuracy of the predicted result, the 
Autodock Vienna and Patchdock tools were also used for 
conducting docking studies using the parameters men-
tioned above. Autodock Vienna generates a genetic algo-
rithm and calculates the binding aﬃnity for the binding 
site of a target protein. On the other hand, the Patchdock 
tool is a geometry-based molecular docking algorithm 
that identiﬁes docking transformations that yield good 
molecular shape complementarities, can also perform 
clustering, and calculates the global BE. The cluster-
ing RMSD value was considered as 2.0 for this analysis. 
Pyridinone showed good binding aﬃnity, i. e., -8.0 Kcal/
mol with the protein and a minimum global free energy 
of -44.35 Kcal/mol, as revealed by Autodock Vienna and 
Patchdock tool, respectively (Table 2). Hence, in the pres-
ent study, pyridinone was conﬁrmed to be an appropri-
ate molecule by using 3 docking tools, and it might be con-
sidered as an antiviral drug candidate in future studies.
4.3. Veriﬁcation of Inhibitors as Suitable Drugs 
The selected ligand molecules were then subjected to 
SN PubChem_Id ΔGtors a ΔGvdw a+ 
ΔGhbond
a + 
ΔGdesolv a
ΔGelec a ΔGintermol a ΔGbinding a ΔGinter a Ki a RMSD a
1. CID_546 1.49 -3.00 -3.23 -6.23 -5.35 -1911.90 120.66 101.968
2. CID_3043 0.60 -5.29 -0.32 -5.61 -5.52 -1912.09 89.46 102.720
3. CID_3414 0.30 -0.91 -5.30 -6.20 -5.91 -1912.93 46.81 96.234
4. CID_3415 1.19 -2.96 -2.87 -5.83 -5.32 -1912.32 126.25 103.468
5. CID_3963 1.49 -6.63 -0.09 -6.72 -6.74 -1912.54 11.47 105.272
6. CID_5718 0.89 -5.59 -0.31 -5.90 -5.78 -1912.77 57.55 98.761
7. CID_5726 1.19 -5.69 -0.16 -5.85 -5.66 -1912.22 71.04 105.693
8. CID_24066 0.60 -5.11 -0.14 -5.25 -5.47 -1912.31 98.30 101.706
9. CID_35370 1.19 -6.89 -0.24 -7.13 -6.95 -1912.61 7.99 104.924
10. CID_47318 0.00 -5.37 0.03 -5.34 -5.34 -1912.42 121.58 105.406
11. CID_50599 0.60 -5.45 -0.36 -5.81 -5.52 -1912.19 89.79 102.718
12. CID_60172 2.39 -5.50 -1.43 -6.94 -5.37 -1911.75 114.91 101.710
13. CID_64993 2.09 -6.76 -0.17 -6.92 -6.15 -1912.26 30.91 105.601
14. CID_65002 1.19 -8.31 0.14 -8.17 -7.55 -1913.21 2.92 99.881
15. CID_449080 1.49 -6.98 0.03 -6.94 -6.69 -1912.75 12.39 105.045
16. CID_451515 1.19 -5.72 -0.14 -5.86 -5.91 -1911.91 46.93 107.086
17. CID_455007 1.19 -6.97 -0.16 -7.12 -6.94 -1912.51 8.16 105.024
18. CID_455194 1.49 -6.82 -0.06 -6.88 -6.73 -1912.59 11.58 105.853
19. CID_455271 0.60 -5.15 -0.19 -5.34 -5.53 -1912.26 88.89 106.698
20. CID_455661 0.89 -5.77 -0.13 -5.90 -5.68 -1912.25 68.08 107.475
21. CID_456314 0.60 -5.66 -0.27 -5.93 -6.19 -1913.20 28.86 106.348
22. CID_676643 0.60 -5.63 -0.32 -5.95 -6.20 -1913.02 28.77 98.684
23. CID_3246700 1.19 -7.02 -0.33 -7.34 -6.38 -1912.57 21.21 103.764
24. CID_4451056 0.60 -1.39 -6.14 -7.53 -5.31 -1911.55 127.36 94.365
25. CID_5742630 0.60 -5.24 -0.25 -5.48 -5.69 -1912.30 67.92 107.627
26. CID_10198219 0.89 -5.59 -0.30 -5.90 -5.78 -1912.61 57.55 98.729
27. CID_11778134 2.39 -5.92 -1.31 -7.23 -5.75 -1911.95 61.19 101.217
28. CID_16219192 0.60 -5.44 -0.39 -5.83 -5.44 -1912.14 103.45 102.652
29. CID_169159 0.60 -6.29 -0.23 -6.52 -5.90 -1912.33 47.44 104.725
Table 1. Autodock Binding Free Energies Calculated Using Diﬀerent Energy Solution and Inhibition Constants
a Abbreviations: ΔGbinding, estimated binding free energy (kcal/mol); ΔGdesolv, desolvation factor of binding free energy (kcal/mol); ΔGelec, electrostatic fac-
tor of binding free energy (kcal/mol); ΔGhbond, H-bonding factor of binding free energy (kcal/mol); ΔGinter, Gibbs free energy of binding (kcal/mol); ΔGinter-
mol, intermolecular energy (kcal/mol); ΔGtors, torsional energy of binding (kcal/mol); ΔGvdw, Vander wall or Lennard–Jones potential factor of binding free 
energy (kcal/mol); Ki, inhibition constant (μM); RMSD, reference root mean square deviation 807
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SN PubChem_Id Autodock 4.0 Autodock Vienna Patchdock
1. CID_65002 -7.55 -8.0 -44.35
2. CID_35370 -6.95 -7.2 -34.82
3. CID_455007 -6.94 -7.2 -35.10
Table 2. Comparative Docking Result Obtained with Various Docking Tools (Energy is Represented in Kcal/mol)
Figure 2. H-Bonds in Inhibitor CID_65002
Figure 3. H-bonds in Inhibitor CID_35370 Figure 4. H-Bonds in Inhibitor CID_455007
Figure 1. Flow Chart of Screening for Inhibitors.
38 Inhibitors Molecules
35
34
32
29 3
Selected for 
Study
2
1
3
Pass
Fail808
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analysis for their pharmacokinetic properties. ADME/T 
was calculated using the preADMET tool, which also 
contains various parameters to identify a potential drug 
candidate. This tool identiﬁed pyridinone out of the 29 
selected ligands as a potential drug candidate. Toxicity 
analysis of pyridinone yielded negative carcinogenicity 
results in both mouse and rat models. ADME/T calcula-
tion revealed that pyridinone had human intestinal 
absorption (%) of 94.65; in vitro Caco-2 cell permeabil-
ity (nm/s), 22.47; in vitro MDCK cell permeability (nm/s), 
7.10; in vitro skin permeability (logKp·cm/h), -4.55; in vi-
tro plasma protein binding (%), 61.24; and in vivo blood 
brain barrier penetration (c.blood/c.brain), 0.13. ADME/T 
properties of the selected molecule were also predicted 
using the PK/DB database. The results of this analysis vali-
dated all ADME/T parameters for the ligand, conﬁrming 
it to be considered a drug candidate. Pyridinone has al-
ready been identiﬁed as an antiviral agent and is also a 
good replication inhibitor. Thus, it fulﬁlls the criteria to 
be considered as a possible drug candidate for the treat-
ment of delta hepatitis.
5. Discussion
Hepatitis D is associated with mortality and morbidity, 
worldwide and therefore, many treatment strategies for 
hepatitis D have been accepted, but none of them have 
been found to be eﬀective. Successful utilization of com-
putational tools and resources has beneﬁted the drug 
discovery studies. Computational approaches have yield-
ed noteworthy and reproducible results with regard to 
drug discovery; and several drugs have been identiﬁed 
using these approaches. These includes ﬂavivirus inhibi-
tors (39), antimalarial agents (40), anti-inﬂuenza mol-
ecules (41), antiSARS drug (42), antiHIV drug (43), Our 
computational analysis suggests that pyridinone can be 
considered as a potential candidate drug for hepatitis 
D. The present study aimed to identify a novel inhibitor 
against HDV by using structure-based drug designing ap-
proach. A docking study conducted for identifying target 
proteins using known computational tools provided a 
clue regarding the molecules that interacted with pos-
sible inhibitor molecules that inhibited the virus replica-
tion and thereby could be used for treating delta hepa-
titis. These results would be beneﬁcial to all researchers 
and pharmaceutical individuals who are conducting 
studies to identify treatment strategies for delta hepati-
tis.
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